Cetuximab (anti-EGFR monoclonal antibody) and bevacizumab (anti-VEGFA monoclonal antibody) enhanced the distribution of the virus in the entire tumor by inhibiting angiogenesis, expanded the number of apoptotic cells, and successfully induced a synergistic anti-tumor effect (88, 89). This evidence concerns the gene EGFR and neoplasm.